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Abstract
Aims The aims of this study were to evaluate health-related quality of life (HRQL) among patients treated with extracorpo-
real membrane oxygenation (ECMO) in northern Norway over a period of 27 years (1988–2015) and to identify variables re-
lated to HRQL.
Methods and results A retrospective inquiry of the ECMO registry at the University Hospital of North Norway identified 74
ECMO-treated patients (mean age 49 years, 65% males). Acute cardiac failure was the dominant indication (58%), and
venoarterial ECMO was the dominant mode of treatment (87%). Mortality for discharged patients was recorded on 20
September 2016. Thirty (41%) survivors were identified. Twenty-three survivors were eligible for the survey and received a
set of questionnaires at home. The main outcome measure was HRQL as measured with the 36-item Short-Form health survey
(SF-36) (RAND Short Form-36 v1.2). Other questionnaires covered demographic information, problems with functioning in
usual daily activities (such as hobbies, household chores, family, or work), employment status, and psychological distress.
The survey was completed by 20 (87%) survivors (mean age = 49 years, 12 men). Indications for ECMO treatment (VA = 90%)
had been respiratory failure (25%), cardiac failure (60%), and extracorporeal cardiopulmonary resuscitation (15%). The average
time since ECMO treatment was 6.5 years. Seventy-five percent reported mental HRQL (SF-36 Mental Component Summary,
mean = 43, SD = 5) or physical HRQL (SF-36 Physical Component Summary, mean = 43, SD = 4.5) within the normal range
(T = 50 ± 10) in comparison with age-matched population data from national norms. Half of the responders reported problems
on the SF-36 subscales general health and role physical. Seventy percent reported problems on the SF-36 subscale role emo-
tional. All but one responder lived independently without any organized care, and 90% reported no problems related to basic
self-care. Half of those in working age had returned to work after ECMO treatment. Forty percent of the responders reported
some degree of restrictions in usual daily activities, problems with mobility (35%), anxiety/depression (35%), or
pain/discomfort (55%). Significant univariate associations were observed for poorer HRQL and higher reports of psychological
distress, pain, and experiencing restrictions in usual everyday activities. Improved HRQL was significantly related to an ex-
tended time since ECMO treatment.
Conclusions Our survey indicates an overall positive long-term HRQL outcome for our ECMO survivors. A subset reported
problems with functioning and HRQL. Future research should focus on identification of the survivors at risk for poor recovery
who may benefit from rehabilitation interventions.
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Introduction
Patient-reported health status is acknowledged as an impor-
tant measure of health in clinical practice and research tri-
als.1 There remains much scope for research to provide
information about the long-term symptom burden, func-
tional status, and quality of life after treatment with extra-
corporeal membrane oxygenation (ECMO), particularly for
adults.2–5
Previous outcome studies show poorer health-related
quality of life (HRQL) in adult survivors of ECMO treatment
than in healthy age-matched and gender-matched controls
but show less difference when ECMO survivors are com-
pared with survivors of cardiac surgery procedures or with
survivors of general intensive care treatment without ECMO
support.2,4–7
In order to improve health status and quality of life in
ECMO survivors with long-term problems, it is important to
characterize which factors do influence their mental HRQL
and physical HRQL.1,7 From previous research, it seems prob-
able that physical impairments with mobility restrictions,3
neurological injuries,8 mental health problems,2,9,10 and cog-
nitive impairments11,12 are potential obstacles for return to
an optimal life situation after ECMO treatment. However, re-
search on influential factors for HRQL in ECMO survivors has
received limited attention.7
In Norway, the first ECMO treatment was performed at the
University Hospital of North Norway (UNN) in 1988.13 From
this initial experience, ECMO was used sporadically at our in-
stitution as an attempted life-saving intervention in critically
ill patients. From January 2013, an institutional ECMO proto-
col was implemented with three principal predefined indica-
tions for treatments such as refractory cardiogenic shock
and severe respiratory failure and as an extracorporeal car-
diopulmonary resuscitation (E-CPR) effort.
The aims of this retrospective, single-institution survey
were to identify the long-term survivors from the entire
treatment era (1988–2015), to clarify their HRQL, and to
characterize influential factors for HRQL.
Methods
Study population and hospital setting
All patients treated with ECMO in the intensive care unit be-
tween 1988 and 2015 at the UNN were identified by
searching the hospital’s electronic databases. The hospital is
located at 69°N and is the primary referral centre for a large
area (112 000 km2), covering the northern part of Norway
and Svalbard with ~500 000 inhabitants. In this region, adult
cardiac surgery and ECMO treatment are localized to one
centre, serving 11 smaller emergency hospitals.
Data collection
Patient medical characteristics were collected by reviewing
hospital records (clinical, laboratory, and operative notes)
from the first registered time of critical illness requiring ECMO
treatment. The standardized data-reporting sheet from the
Extracorporeal Life Support Organization (https://www.elso.
org/Portals/0/Files/ELSOECLSRegistryForm.pdf) was used to
guide the documentation of patient characteristics, pre-ECMO
and on-ECMO clinical status, laboratory information, compli-
cating events requiring intervention during ECMO treatment,
and the causes of death.14 Owing to the long time-span of in-
clusion and the heterogeneity of the indications and patient
treatments over this time period, we have presented our pa-
tients’ medical characteristics in three temporal cohorts:
1988–2000, 2001–12, and 2013–15. The last period represents
the time after introduction of a predefined inclusion protocol
(date 1 January 2013).
Mortality after discharge was recorded in 20 September
2016. Written consent for study participation was obtained
by mail from long-term survivors. The survey was sent only
to survivors aged ≥18 years and without documentation of ex-
tensive cognitive problems (two patients excluded). Inclusion
and exclusion of survivors for the survey are shown in Figure 1.
The study complies with the Declaration of Helsinki15 and
was approved by the Regional Committee for Research Ethics
in Medicine and Health Sciences in North Norway (Institu-
tional Protocol Number 2015/1068).
Measurement methods
HRQL was measured with the Norwegian standard Version
1.2 of the 36-item Short-Form health survey (SF-36).16 SF-36
is a generic, profile-based HRQL measure designed to capture
a person’s perception of how his or her health status has in-
terfered with his or her psychological, social, and physical
functioning for the past 4 weeks. It provides a measure of
the relative burden of disease along eight different dimen-
sions of health within a Physical Component Summary (PCS)
scale and a Mental Component Summary (MCS) scale. Each
participant’s data were scored according to the recom-
mended procedure and then compared with age-corrected
normative data from the general Norwegian population.16,17
Age-corrected scores were then transformed into T-scores
(mean = 50, SD = 10) such that scores between 40 and 60 rep-
resent the statistical normal range for all subscales and sum-
mary component scales.
Information about problems related to mobility (walking),
self-care (washing/dressing), usual activities (work, study,
housework, family, leisure activities), pain/discomfort, and
anxiety/depression were assessed with the descriptive sys-
tem of the EuroQoL five-dimension five-level (EQ-5D-5L)
health questionnaire.18 Each of the five dimensions is rated
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on a 5-point scale, ranging from 1 ‘no problems’ to 5 ‘ex-
treme problems’.
Psychological distress was assessed using the Hospital
Anxiety and Depression Scale (HADS).19 The HADS is a
14-item questionnaire designed to assess symptoms of mood
disorders in non-psychiatric hospital outpatients. Seven ques-
tions assess anxiety symptoms, and seven assess symptoms
of depression (scored 0–3 for each question), with each scale
having a maximum score of 21. Scores at or above eight
points on either the depression or anxiety scale are suggested
to be clinically relevant.20
Cognitive problems were assessed with the Everyday
Memory Questionnaire 13-item version (EMQ-R).21 The
EMQ-R consists of 13 items, where each item is rated on a
5-point scale ranging from A, scored as zero (‘Once or less
in the last month’), to E, scored as four (‘Once or more in a
day’). The items were summed and given a scale in the range
of 0–52. The summary score was evaluated for its correlation
with mental HRQL and physical HRQL.
Statistical analyses
We used descriptive statistics to present demographic and
medical characteristics of the participants and their scores
on the questionnaires. Continuous variables were reported
as mean (standard deviation and/or range), while categorical
variables were reported as counts (percent). Group compari-
sons of variables between the three time cohorts were
analysed by one-way ANOVA or binary logistic regression.
The SF-36 PCS and MCS scores were not significantly different
from a normal distribution, as shown by the Shapiro–Wilk
tests and by inspection of Q–Q plots of the residuals. Hence,
parametric testing was used to assess group differences and
correlations with the PCS and MCS SF-36 variables. A signifi-
cance level of P < 0.05 was used. All statistical analyses were
performed using SPSS 25.0 (IBM, SPSS Inc., Chicago, IL, USA).
Results
Patients treated with extracorporeal membrane
oxygenation, 1988–2015
As shown in Table 1, the total number of ECMO-treated pa-
tients was 74, with a marked increase after implementation
of the institutional protocol in 2013. Most patients treated
with ECMO at our hospital were adult men (65%), mean
age 49 years (0–76), and the main indication for support
Figure 1 Flow chart shows the inclusion and exclusion of survivors for the survey. ECMO, extracorporeal membrane oxygenation; VA, venoarterial; VV,
venovenous.
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was acute cardiac failure (58%). In the large majority (>90%)
of these patients, the cardiac failure was new onset without
any known cardiac diseases prior to ECMO treatment.
Venoarterial (VA) ECMO treatment was the dominant config-
uration (87%). Venovenous (VV) ECMO was used only sporad-
ically (14%). The average duration of ECMO support was
6 days (8 h to 21 days), with an average hospital stay of 19
(1–126) days.
Survival rates for the different indications for ECMO treat-
ment are shown in Table 1. Survival rates were not signifi-
cantly different between the three time cohorts. The main
effect of age was not significantly different between the co-
horts [F(2, 73) = 5.7, P = 0.005]. However, adult patients
treated in the first cohort (1988–2000) were significantly
younger than adults treated between 2013 and 2015
(P = 0.001) and adults treated between 2001 and 2012
(P = 0.024).
Complications during ECMO support and the causes of
early deaths are shown in Table 2. The most common causes
of death were irreversible organ failure involving the brain or
the heart in the VA group and multiorgan failure in the VV
group. All but four deaths occurred within 30 days. One pa-
tient died after 90 days, one after 15 months, and two after
7 and 26 years.
In survivors of VA ECMO treatment, cardiopulmonary com-
plications were the most frequent, followed by haemorrhagic
and renal complications. These complications occurred at a
higher rate in the VA group that died, as did metabolic
Table 1 Characteristics of patients treated with extracorporeal membrane oxygenation in the three time cohorts and the total sample
Characteristics of ECMO-treated
patients in the three time
cohorts (n = 74)
1988–2000
n = 10 (14%)
2001–12
n = 16 (22%)
2013–15











Age (years) 31 (21) (0–58) 48 (21) (0–73) 52 (16) (2–76) 48.6 (0–76)
Age < 18 2 (20) 1 (6) 2 (4) 5 (7)
Male 5 (50) 12 (75) 31 (65) 48 (65)
ECMO mode
VA 7 (70) 15 (94) 42 (87.5) 64 (86.5)
VV 3 (30) 1 (6) 6 (12.5) 10 (13.5)
Reason for support
Cardiac; all indications 2 (20) 12 (75) 29 (60) 43 (58)
Cardiogenic shock 0 8 18 26
Post-cardiotomy 2 4 11 17
Pulmonary 5 (50) 1 (6) 7 (15) 13 (18)
E-CPR 3 (30) 3 (19) 12 (25) 18 (24)
Bridge to transplant 0 3 (19) 3 (6) 6 (8)
Days ventilated pre-ECMO 4 (10) (0–26) 0.25 (0.4) (0–1) 0.6 (1.5) (0–9) 0.9 (0–26)
Pre-pH < 7.2 4 (40) 8 (50) 24 (50) 36 (49)
Cardiac arrest pre-ECMO 3 (30) 6 (38) 27 (56) 36 (49)
Cannulation
Central/peripheral 2/4 (20/40) 1/11 (6/69) 4/39 (8/81) 7/54 (10/73)
Surgical/percutaneous 4/2 (40/20) 11/1 (69/6) 41/2 (86/4) 56/5 (76/7)
Not registered 4 (40) 4 (25) 5 (10) 13 (17)
Days on ECMO 6 (6) (1–21) 4.5 (3) (0.3–14) 6.6 (6) (0.3–21) 6 (0.3–21)
Days of hospital stay 15 (10) (5–29) 13 (10) (1–35) 21 (26) (1–125) 19 (1–125)
Discharged ongoing ECMO 0 2 (13) 6 (13) 8 (11)
Survived ECMO 6 (60) 8 (50) 28 (58) 42 (57)
Survived 30 days 5 (50) 7 (44) 22 (46) 34 (46)
Cardiac; all indications 0 5 (42) 13 (45) 18 (42)
Cardiogenic shock 0 3 (38) 11 (61) 14 (54)
Post-cardiotomy 0 2 (50) 2 (19) 4 (24)
Pulmonary 3 (60) 1 (100) 4 (57) 8 (62)
E-CPR 2 (67) 1 (33) 5 (42) 8 (44)
Survivors with neurological injury
Central 0 0 5 (23) 5 (15)
Peripheral 2 (40) 1 (14) 7 (32) 10 (29)
ECMO set-up was defined by the last configuration used. The occurrence of neurological injuries in survivors is as described by discharge
note information.
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complications. Least frequent in the surviving VA group were
complications related to the lower extremities and central
nervous system (CNS) complications. These complications
were more common among the patients who died than
among those who survived VA ECMO. Complications involv-
ing the CNS or the lower extremities did not occur in the
Table 2 Complications requiring intervention during extracorporeal membrane oxygenation support in the 30 day survivors and
non-survivors, and causes of death for venoarterial and venovenous extracorporeal membrane oxygenation shown separately
Complications requiring intervention during
ECMO support in the 30 day survivors and
non-survivors, and causes of death
Survived VA
n = 29 18 men
Age 42 (0–73)
Died
n = 35 25 men
Age 54 (2–76)
Survived VV
n = 5, 4 men
Age 50 (22–68)
Died
n = 5 1 man
Age 44 (18–57)
Mechanical complications
Cannula problems 24% (7) 26% (9) 20% (1) 20% (1)
Other 14% (4) 6% (2) 20% (1) 40% (2)
Patient related complications
Haemorrhagic
GI haemorrhage 24% (7) 9% (3) 20% (1) 20% (1)
Cannulation site bleeding 52% (15) 49% (17) 20% (1) 40% (2)
Surgical site bleeding 14% (4) 29% (10) 20% (1) 20% (1)
Haemolysis (plasma Hgb > 50 mg/dL) 3% (1) 0 0 0
DIC 7% (2) 3% (1) 0 0
Central nervous systema
Infarction 7% (2) 11% (4) 0 0
Haemorrhage 0 6% (2) 0 0
Brain death 0 9% (3) 0 0
Renal
1.5 < creatinine < 3.0 mg/L 45% (13) 40% (14) 20% (1) 0
Creatinine > 3 mg/L 14% (4) 17% (6) 0 20% (1)
Haemodialysis 28% (8) 37% (13) 0 40% (2)
Haemofiltration 10% (3) 29% (10) 20% (1) 20% (1)
CAVHD 0 0 0 20% (1)
Pulmonary
Pneumothorax 7% (2) 6% (2) 0 0
Pulmonary haemorrhage 10% (3) 17% (6) 0 20% (1)
Cardiopulmonary
Inotropes on ECLS 52% (15) 83% (29) 80% (4) 80% (4)
Myocardial stunning by echocardiography 17% (5) 26% (9) 0 0
Hypertension requiring vasodilator 14% (4) 9% (3) 0 0
Tamponade: blood 17% (5) 20% (7) 0 0
CPR required 10% (3) 11% (4) 0 0
Cardiac arrhythmia 31% (9) 57% (20) 0 0
Other 3% (1) 6% (2) 0 0
Infectious
Culture proven new infection 24% (7) 20% (7) 0 0
WBC < 1500 0 0 0 20% (1)
Metabolic
Glucose < 40 mg/L 7% (2) 20% (7) 0 0
Glucose > 240 mg/L 3% (1) 0 0 0
pH < 7.20 24% (7) 43% (15) 20% (1) 40% (2)
pH > 7.6 7% (2) 0 0 0
Hyperbilirubinaemia 21% (6) 31% (11) 0 40% (2)
Lower extremity
Limb ischaemia 0 3% (1) 0 0
Compartment syndrome 0 3% (1) 0 0
Fasciotomy 0 6% (2) 0 0
Amputation 3% (1) 0 0 0
Causes of death




Other organ 25% (4)
Multiorgan failure 34% (12) 80% (4)
Haemorrhage 3% (1)
Not registered 17% (6)
All but one early death occurred within 30 days.
CAVHD, continuous arteriovenous haemodialysis; DIC, disseminated intravascular coagulation; ECLS, extracorporeal life support; GI, gas-
trointestinal; Hgb, haemoglobin; WBC, white blood cell.
aAs verified by computed tomography.
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VV group for either survivors or non-survivors. Cardiopulmo-
nary and haemorrhagic complications were most frequent in
the group of VV survivors, while additional renal and
metabolic complications occurred at a high rate in the non-
survivors of VV ECMO treatment. No patients required long-
term renal replacement therapy.
Additional discharge note information of neurological inju-
ries is shown in Table 1. Five survivors of VA ECMO suffered
CNS injuries. All events occurred after 2013. The CNS injuries
were verified by cerebral imaging during hospital stay and
were described as cerebral infarction, cerebral bleeding, or
hypoxic–ischaemic brain injury. All five patients had under-
gone VA ECMO treatment for either cardiogenic shock
(40%) or E-CPR (60%). One of them also suffered peripheral
nerve injury. All five were resuscitated from cardiac arrest.
Peripheral neural injuries were registered in 10 survivors
(29%), equally distributed over the three time cohorts, and
occurred in all indications: pulmonary (P) (20%), E-CPR
(20%), and cardiac (C) (60%). Peripheral neuropathies were
most often foot drop or critical illness polyneuropathies.
Survey responders
The survey responders were 12 men and 8 women, with an
average age of 48 (SD = 16) years. The average time from
ECMO to follow-up was 6.5 (SD = 7) years, and 60% of the re-
sponders had been treated after implementation of the insti-
tutional ECMO protocol in 2013. One of the responders had
been a child at the time of ECMO treatment. Seventy-five
percent were treated with VA ECMO, for C (60%), P (25%),
or E-CPR (15%) indications. The average time on ECMO was
8 (SD = 7) days, and the average time of hospital stay was
20 (SD = 14) days. Peripheral neurological sequelae were doc-
umented in six (30%) survey responders and CNS injury in one
responder (5%). Information about current chronic disorders
requiring outpatient treatment was collected from the survey
responders’ hospital journals and showed that 11 (55%) were
receiving outpatient treatment for a chronic cardiac condi-
tion, 4 (20%) had diabetes, 2 (10%) had a chronic pulmonary
condition, 1 had cancer, and 1 had renal disease. The demo-
graphic characteristics of the survey responders are shown in
Table 3, and the results from the survey are displayed in
Table 3 and Figures 2 and 3.
EuroQoL five dimensions five levels
As shown in Figure 2, the majority of the responders reported
no problems with mobility (65%), self-care (90%), usual
everyday activities (60%), with anxiety/depression (65%).
None reported extreme problems, and severe problems
were unusual (n = 1). However, slight or moderate
problems were reported for self-care (10%), mobility (35%),
anxiety/depression (35%), usual activities (40%), and
pain/discomfort (55%). As shown in Table 3, all were living
in their private homes, and the large majority reported
receiving no organized care. Fifty percent of those of working
age had returned to work.
36-Item Short-Form health survey
The SF-36 results are displayed in Figure 3 and Table 3. The
average MCS and PCS scores were in the low normal range
than were age-matched national population norms. The sub-
scales for general health, emotional role functioning, and
physical role functioning were below the normal range.
Table 3 shows the number of individuals with HRQL scores
below the normal range (T < 40) on each of the SF-36 scales.
Seven (35%) survivors scored below the normal range on the
PCS and/or MCS scales. These individuals were all long-term
survivors of VA ECMO for cardiac (n = 6) or E-CPR (n = 1)
indications.
Table 3 Demographic characteristics of the survey responders and
their results from the questionnaires
Result from the survey responders n = 20 n (%) or mean (SD)
Male/female 12 (60)/8 (40)
Current age 48 (15)
Marital status
Alone 7 (35)
Married/with partner 13 (65)
Living situation
Home independent 18 (90)
Home with help from others 2 (10)
Sheltered housing/nursing home 0
Education
Primary school 5 (25)
High school 13 (65)
University level 2 (10)
Working situation
Full time 7 (35)
Part time 1 (5)
Retired 4 (20)
Disability pension 8 (40)
Psychological distress
HADS depression scale 3 (2.6)
HADS anxiety scale 4.5 (4)
HADS depression scale > 8 0
HADS anxiety scale > 8 3 (15)
Cognitive complaints
EMQ-13 score 10 (9)
SF-36
Mental Component Summary (MCS) 43 (5), n < 40 = 5
Physical Component Summary (PCS) 43 (4.5), n < 40 = 5
Physical functioning 50 (10), n < 40 = 3
General health 38 (11), n < 40 = 11
Role physical 38 (13), n < 40 = 10
Role emotional 35 (13), n < 40 = 14
Social role 45 (11), n < 40 = 6
Emotional well-being 49 (9), n < 40 = 3
Pain 47 (9), n < 40 = 4
Vitality 43 (11), n < 40 = 5
SF-36 scores shown as both mean (SD) and the number of individ-
uals with T-scores < 40 on each scale.
EMQ-13, Everyday Memory Questionnaire—13-item version;
HADS, Hospital Anxiety and Depression Scale.
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Hospital Anxiety and Depression Scale
No patients reported symptoms above the clinical cut-off on
the depression scale. Three (15%) responders reported symp-
toms above the clinical cut-off on the anxiety scale. HADS
scores are shown in Table 3.
Correlations with health-related quality of life
Poorer MCS scores on the SF-36 were significantly correlated
with more cognitive problems as reported on the EMQ-R
(r = 0.64, P = 0.002) and more symptoms of anxiety
(r = 0.50, P = 0.026) and depression (r = 0.63, P = 0.003)
Figure 2 EQ-5D-5L. Frequency (percentage) of the severity of problems in daily functioning reported by the ECMO-treated long-term survivors on the
EQ-5D-5L functional system (n = 20). ECMO, extracorporeal membrane oxygenation; EQ-5D-5L, EuroQoL five dimensions five levels.
Figure 3 SF-36 scores from all eight subscales and the two component summary scales presented in standardized T-scores (mean = 50, SD = 10).
Coloured bars show mean; error bars show SD. A T-score within 40 to 60 represents the statistical normal range. Dashed horizontal line represents
the lower limit of the normal range. Higher scores indicate better HRQL. HRQL, health-related quality of life; MCS, Mental Component Summary; PCS,
Physical Component Summary; SF-36, 36-item Short-Form health survey.
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as reported on the HADS. Also, a significantly lower MCS
score was correlated with a higher degree of difficulties with
personal care (r = 0.45, P = 0.046) and pain/discomfort
(r = 0.46, P = 0.042) as reported on the EQ-5D-5L.
Poorer PCS scores on the SF-36were significantly correlated
with higher reports of depression symptoms as reported on
the HADS (r = 0.63, P = 0.003) and with the EQ-5D-5L do-
mains of pain/discomfort (r = 0.65, P = 0.002) and problems
with handling daily activities (r = 0.45, P = 0.04).
Patients’ demographic variables (age, sex, education, mar-
ital status, return to work) or ECMO characteristics (mode, in-
dication, duration of ECMO support) were not significantly
associated with the MCS or PCS scores. Survivors treated
prior to 2013 had significantly better HRQL scores than had
survivors treated after 2013, indicative of better HRQL with
longer time since treatment [MCS: F(1, 19) = 4.5, P = 0.48;
PCS: F(1, 19) = 4.5, P = 0.49].
Discussion
We identified all ECMO-treated patients from the UNN during
a 27 year period and evaluated HRQL in adult survivors. De-
spite increasing patient volume, wider indications, and older
patients accepted in recent times, survival rates have been rel-
atively stable and compare well with international reports.22
The main observation from our follow-up demonstrated
that our survivors had mental HRQL and physical HRQL in
the statistical lower normal range compared with age-
matched national data. Psychological distress was low, and
50% of survivors had returned to work. Longer time since
treatment was associated with improved HRQL. Psychological
distress, memory problems, pain, and difficulties with usual
activities were significantly correlated with a poorer HRQL.
It should be noted that our SF-36 profile showed poor
scores on the subscale for general health and on the sub-
scales for emotional and physical role functioning. It is likely
that the general health subscale mirrors not only the adverse
effects of past critical illness and ECMO treatment but also
the chronic diseases that were frequent in our long-term sur-
vivors. Poor results on the two role-functioning subscales are
likely related to half of our sample not having returned to
work after ECMO treatment.
Firm comparisons with previous HRQL studies are compli-
cated by heterogeneity in patient and treatment characteris-
tics, comparator groups, and follow-up times. Nevertheless,
earlier studies have also reported acceptable, although vari-
able, HRQL when using the SF-36.2,4,5,23–25 High rates of return
to independence in self-care and daily activities, as found in
the present study, have also been reported previously in other
studies using the EQ-5D descriptive system.3,7,23,24,26,27
Our registered levels of psychological distress are low com-
pared with those of several other studies using the
HADS.2,3,5,9,10 In a prospective longitudinal study, Tramm
et al. found that mental health improved during the first year
after ECMO and that psychological distress was higher in sur-
vivors who received psychological care prior to ECMO treat-
ment.3 Somewhat at odds with this finding, Risnes et al.
found high rates of psychiatric morbidity several years after
ECMO treatment, even in the survivors with no history of psy-
chiatric disorder prior to ECMO treatment.9 Our 50% return-
to-work rate is higher than that found by Hodgson et al.28
and Camboni et al.26 but lower than that reported by Tramm
et al.,3 where two-thirds of the sample had returned to work
by 1 year after ECMO treatment.
In accordance with a number of previous studies, we
showed that HRQL improves with longer time since ECMO
treatment.2,3,5,7,10,25 Although this result is encouraging,
health workers should prioritize to identify survivors at risk
for a poor HRQL, as well as factors that may hamper and fa-
cilitate HRQL after survival at the various time points in the
recovery process.7,23 In the present study, the subgroup of
responders with a poor overall HRQL was survivors of VA
ECMO for cardiogenic shock or E-CPR indications. Prior stud-
ies suggest that these ECMO survivors are at higher risks for
neurological injuries and cognitive impairments.8,11 In our
survivors, we detected mainly peripheral nerve injuries and,
to a much lesser extent, CNS injuries. Without recent neuro-
imaging and neuropsychological testing, it remains uncertain
if some of the survivors in our study had neurocognitive im-
pairments that affected their functioning or HRQL.3,5,8,11,12
In the present study, more symptoms of psychological dis-
tress, memory problems, and pain, as well as difficulties with
usual activities in everyday life, were significantly correlated
with a poorer HRQL. If replicated in future studies, preferably
with larger samples, our presented correlations may suggest
that these issues need consideration in follow-up care after
survival and in upcoming research on HRQL after successful
ECMO treatment.5,6,29,30
Our study is limited by retrospective data retrieval prone
to lack of precision and bias. Data were collected from a sin-
gle centre over a long period of time, which limits generaliz-
ability. The small sample sizes prohibited multivariable
modelling and statistical analyses regarding the subgroups
of patients and long-term survivors. Confounders may influ-
ence our observed correlations. HRQL prior to ECMO treat-
ment was not known. HRQL was assessed at only one
occasion and the responders varied greatly in time since
ECMO treatment. Loss to follow-up and exclusion of two
long-term survivors with brain injury may have skewed the
outcome measures in a positive direction.
The strengths of our survey are the long follow-up times
and the fact that HRQL and functional outcome were evalu-
ated with generic questionnaires commonly used in the
ECMO literature and generally well validated in several popu-
lations. Nevertheless, psychometric validation of HRQL instru-
ments in the ECMO population has yet to be performed.
Additionally, it is currently unclear which instruments best
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capture the outcomes that are most important to the survi-
vors at various time points after ECMO treatment.7,29 Studies
of HRQL in adult ECMO survivors with neurological injuries
are currently lacking and should receive future attention to
inform rehabilitation services. For the subgroup of ECMO pa-
tients with CNS injury, alternatives to generic HRQL question-
naires should be considered, as should the inclusion of
measures of neuropsychological functioning.1,3,5,11 Influential
factors for HRQL after successful ECMO survival warrants fur-
ther evaluation to inform researchers and practitioners re-
garding potential targets for rehabilitation interventions.1,5,7
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